NCT05890950View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

July 12, 2023

Study Completion Date

July 12, 2023

Conditions
ObesityType 2 Diabetes Mellitus in Obese
Interventions
DRUG

K-757 and K-833

Both administered orally

DRUG

Matching placebo to K-757 and K-833

Both administered orally

Trial Locations (1)

19711

QPS, LLC, Newark

Sponsors

Lead Sponsor

Kallyope Inc.
All Listed Sponsors
lead

Kallyope Inc.

INDUSTRY

NCT05890950 - A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter